200 related articles for article (PubMed ID: 32197509)
1. HO-1 Interactors Involved in the Colonization of the Bone Niche: Role of ANXA2 in Prostate Cancer Progression.
Anselmino N; Bizzotto J; Sanchis P; Lage-Vickers S; Ortiz E; Valacco P; Paez A; Labanca E; Meiss R; Navone N; Cotignola J; Vazquez E; Gueron G
Biomolecules; 2020 Mar; 10(3):. PubMed ID: 32197509
[TBL] [Abstract][Full Text] [Related]
2. Heme oxygenase-1 (HO-1) expression in prostate cancer cells modulates the oxidative response in bone cells.
Ferrando M; Wan X; Meiss R; Yang J; De Siervi A; Navone N; Vazquez E
PLoS One; 2013; 8(11):e80315. PubMed ID: 24224047
[TBL] [Abstract][Full Text] [Related]
3. Heme Oxygenase-1 Is a Pivotal Modulator of Bone Turnover and Remodeling: Molecular Implications for Prostate Cancer Bone Metastasis.
Anselmino N; Starbuck M; Labanca E; Cotignola J; Navone N; Gueron G; Zenclussen AC; Vazquez E
Antioxid Redox Signal; 2020 Jun; 32(17):1243-1258. PubMed ID: 31861963
[No Abstract] [Full Text] [Related]
4. Heme oxygenase-1 in the forefront of a multi-molecular network that governs cell-cell contacts and filopodia-induced zippering in prostate cancer.
Paez AV; Pallavicini C; Schuster F; Valacco MP; Giudice J; Ortiz EG; Anselmino N; Labanca E; Binaghi M; Salierno M; Martí MA; Cotignola JH; Woloszynska-Read A; Bruno L; Levi V; Navone N; Vazquez ES; Gueron G
Cell Death Dis; 2016 Dec; 7(12):e2570. PubMed ID: 28032857
[TBL] [Abstract][Full Text] [Related]
5. PTEN deletion and heme oxygenase-1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome.
Li Y; Su J; DingZhang X; Zhang J; Yoshimoto M; Liu S; Bijian K; Gupta A; Squire JA; Alaoui Jamali MA; Bismar TA
J Pathol; 2011 May; 224(1):90-100. PubMed ID: 21381033
[TBL] [Abstract][Full Text] [Related]
6. Myxovirus Resistance Protein 1 (MX1), a Novel HO-1 Interactor, Tilts the Balance of Endoplasmic Reticulum Stress towards Pro-Death Events in Prostate Cancer.
Ortiz E; Sanchis P; Bizzotto J; Lage-Vickers S; Labanca E; Navone N; Cotignola J; Vazquez E; Gueron G
Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32640729
[TBL] [Abstract][Full Text] [Related]
7. Signal transducer and activator of transcription 6 (STAT6) is a novel interactor of annexin A2 in prostate cancer cells.
Das S; Shetty P; Valapala M; Dasgupta S; Gryczynski Z; Vishwanatha JK
Biochemistry; 2010 Mar; 49(10):2216-26. PubMed ID: 20121258
[TBL] [Abstract][Full Text] [Related]
8. Critical role of endogenous heme oxygenase 1 as a tuner of the invasive potential of prostate cancer cells.
Gueron G; De Siervi A; Ferrando M; Salierno M; De Luca P; Elguero B; Meiss R; Navone N; Vazquez ES
Mol Cancer Res; 2009 Nov; 7(11):1745-55. PubMed ID: 19903769
[TBL] [Abstract][Full Text] [Related]
9. Secretome analysis of an osteogenic prostate tumor identifies complex signaling networks mediating cross-talk of cancer and stromal cells within the tumor microenvironment.
Lee YC; Gajdosik MS; Josic D; Clifton JG; Logothetis C; Yu-Lee LY; Gallick GE; Maity SN; Lin SH
Mol Cell Proteomics; 2015 Mar; 14(3):471-83. PubMed ID: 25527621
[TBL] [Abstract][Full Text] [Related]
10. Unveiling the association of STAT3 and HO-1 in prostate cancer: role beyond heme degradation.
Elguero B; Gueron G; Giudice J; Toscani MA; De Luca P; Zalazar F; Coluccio-Leskow F; Meiss R; Navone N; De Siervi A; Vazquez E
Neoplasia; 2012 Nov; 14(11):1043-56. PubMed ID: 23226098
[TBL] [Abstract][Full Text] [Related]
11. Heme oxygenase-1 in macrophages controls prostate cancer progression.
Nemeth Z; Li M; Csizmadia E; Döme B; Johansson M; Persson JL; Seth P; Otterbein L; Wegiel B
Oncotarget; 2015 Oct; 6(32):33675-88. PubMed ID: 26418896
[TBL] [Abstract][Full Text] [Related]
12. Prognostic features of Annexin A2 expression in prostate cancer.
Tan SH; Young D; Chen Y; Kuo HC; Srinivasan A; Dobi A; Petrovics G; Cullen J; Mcleod DG; Rosner IL; Srivastava S; Sesterhenn IA
Pathology; 2021 Feb; 53(2):205-213. PubMed ID: 32967771
[TBL] [Abstract][Full Text] [Related]
13. MIEN1, a novel interactor of Annexin A2, promotes tumor cell migration by enhancing AnxA2 cell surface expression.
Kpetemey M; Dasgupta S; Rajendiran S; Das S; Gibbs LD; Shetty P; Gryczynski Z; Vishwanatha JK
Mol Cancer; 2015 Aug; 14():156. PubMed ID: 26272794
[TBL] [Abstract][Full Text] [Related]
14. Heme Oxygenase 1 Impairs Glucocorticoid Receptor Activity in Prostate Cancer.
Leonardi DB; Anselmino N; Brandani JN; Jaworski FM; Páez AV; Mazaira G; Meiss RP; Nuñez M; Nemirovsky SI; Giudice J; Galigniana M; Pecci A; Gueron G; Vazquez E; Cotignola J
Int J Mol Sci; 2019 Feb; 20(5):. PubMed ID: 30813528
[TBL] [Abstract][Full Text] [Related]
15. Rack1 mediates tyrosine phosphorylation of Anxa2 by Src and promotes invasion and metastasis in drug-resistant breast cancer cells.
Fan Y; Si W; Ji W; Wang Z; Gao Z; Tian R; Song W; Zhang H; Niu R; Zhang F
Breast Cancer Res; 2019 May; 21(1):66. PubMed ID: 31113450
[TBL] [Abstract][Full Text] [Related]
16. ERG oncoprotein inhibits ANXA2 expression and function in prostate cancer.
Griner NB; Young D; Chaudhary P; Mohamed AA; Huang W; Chen Y; Sreenath T; Dobi A; Petrovics G; Vishwanatha JK; Sesterhenn IA; Srivastava S; Tan SH
Mol Cancer Res; 2015 Feb; 13(2):368-79. PubMed ID: 25344575
[TBL] [Abstract][Full Text] [Related]
17. Annexin A2 positively contributes to the malignant phenotype and secretion of IL-6 in DU145 prostate cancer cells.
Inokuchi J; Narula N; Yee DS; Skarecky DW; Lau A; Ornstein DK; Tyson DR
Int J Cancer; 2009 Jan; 124(1):68-74. PubMed ID: 18924133
[TBL] [Abstract][Full Text] [Related]
18. Annexin 2-CXCL12 interactions regulate metastatic cell targeting and growth in the bone marrow.
Jung Y; Wang J; Lee E; McGee S; Berry JE; Yumoto K; Dai J; Keller ET; Shiozawa Y; Taichman RS
Mol Cancer Res; 2015 Jan; 13(1):197-207. PubMed ID: 25139998
[TBL] [Abstract][Full Text] [Related]
19. Caprylic acid (C8:0) promotes bone metastasis of prostate cancer by dysregulated adipo-osteogenic balance in bone marrow.
Wang C; Wang J; Chen K; Pang H; Li X; Zhu J; Ma Y; Qiu T; Li W; Xie J; Zhang J
Cancer Sci; 2020 Oct; 111(10):3600-3612. PubMed ID: 32770813
[TBL] [Abstract][Full Text] [Related]
20. The MET/Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted Tyrosine Kinase Inhibitor Also Attenuates FMS-dependent Osteoclast Differentiation and Bone Destruction Induced by Prostate Cancer.
Watanabe K; Hirata M; Tominari T; Matsumoto C; Fujita H; Yonekura K; Murphy G; Nagase H; Miyaura C; Inada M
J Biol Chem; 2016 Sep; 291(40):20891-20899. PubMed ID: 27539855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
